6-(2-hydroxyethylamino)-3-propyl-7H-purin-2(3H)-one | 135839-57-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-(2-hydroxyethylamino)-3-propyl-7H-purin-2(3H)-one
• 英文别名: 6-<(hydroxyethyl)amino>-3-propyl-7(9H)-purin-2-one；3,7-dihydro-6-(2-hydroxyethylamino)-3-n-propyl-2H-purin-2-one；6-(2-hydroxyethylamino)-3-propyl-7H-purin-2-one
• CAS: 135839-57-5
• 化学式: C₁₀H₁₅N₅O₂
• 分子量: 237.261
• InChiKey: VWYIIVKJULRBGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  93.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(2-hydroxyethylamino)-3-propyl-7H-purin-2(3H)-one 在 sodium hydride 、 三氯氧磷 作用下， 反应 1.17h， 生成 7,8-dihydro-1-methyl-4-propyl-1H-imidazo<2,1-i>purin-5(4H)-one
  参考文献：
  名称：

  三环嘌呤衍生物的便捷合成

  摘要：

  方便合成新的杂环，例如7,8-dihydro-1 H-咪唑并[2,1- i ] purin-5（4 H）-ones（2，n = 0）和5,6-dihydro-1 H描述了-咪唑并[2，1 - b ]嘌呤-9（8 H）-一（3）。通过处理6-甲硫基-7 H-嘌呤-2（3- H）-ones 7或2-苄硫基-1-甲基-9-三苯基甲基-9 H-嘌呤-6（1 ）来完成2和3的合成。H）一（15）和适当的氨基醇，然后使用亚硫酰氯进行脱水环化。通过6-羟基-2-巯基嘌呤（12）的苄基化，三苯甲基化和N-甲基化来有效地制备化合物15。

  DOI：

  10.1002/jhet.5570300141
• 作为产物：
  描述：

  3-丙基-6-硫代黄嘌呤 在 sodium hydroxide 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 3.0h， 生成 6-(2-hydroxyethylamino)-3-propyl-7H-purin-2(3H)-one
  参考文献：
  名称：

  三环嘌呤衍生物的便捷合成

  摘要：

  方便合成新的杂环，例如7,8-dihydro-1 H-咪唑并[2,1- i ] purin-5（4 H）-ones（2，n = 0）和5,6-dihydro-1 H描述了-咪唑并[2，1 - b ]嘌呤-9（8 H）-一（3）。通过处理6-甲硫基-7 H-嘌呤-2（3- H）-ones 7或2-苄硫基-1-甲基-9-三苯基甲基-9 H-嘌呤-6（1 ）来完成2和3的合成。H）一（15）和适当的氨基醇，然后使用亚硫酰氯进行脱水环化。通过6-羟基-2-巯基嘌呤（12）的苄基化，三苯甲基化和N-甲基化来有效地制备化合物15。

  DOI：

  10.1002/jhet.5570300141

文献信息

• Condensed purine derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05270316A1

  公开（公告）日：1993-12-14

  There are disclosed condensed purine derivatives represented by formula; ##STR1## in which R.sup.3 represents hydrogen, lower alkyl or benzyl; each of X.sup.1 and X.sup.2 independently represents hydrogen, lower alkyl, aralkyl or phenyl; and n is an integer of 0 or 1; R.sup.1 represents hydrogen, lower alkyl, alicyclic alkyl, noradamantan-3-yl, dicyclopropylmethyl or styryl; and R.sup.2 represents hydrogen, lower alkyl or alicyclic alkyl; or a pharmaceutically acceptable salt thereof. The derivatives and pharmaceutically acceptable salts are useful as diuretics, renal protecting agents, antiallergic agents and hypotensives.

  公式表示的披露的浓缩嘌呤衍生物如下；##STR1## 其中R.sup.3代表氢、较低的烷基或苄基；X.sup.1和X.sup.2中的每一个独立地代表氢、较低的烷基、芳基烷基或苯基；n是0或1的整数；R.sup.1代表氢、较低的烷基、脂环烷基、诺伊达曼丹-3-基、二环丙基甲基或苯乙烯基；R.sup.2代表氢、较低的烷基或脂环烷基；或其药学上可接受的盐。这些衍生物和药学上可接受的盐可用作利尿剂、肾脏保护剂、抗过敏剂和降压剂。
• Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase:  Heterocycle-Condensed Purines
  作者：Hiroyuki Sawanishi、Hirokazu Suzuki、Shinya Yamamoto、Yoshihiro Waki、Shohei Kasugai、Keiichi Ohya、Nagao Suzuki、Ken-ichi Miyamoto、Kenzo Takagi

  DOI：10.1021/jm970089s

  日期：1997.9.1

  To reverse the adverse reactions of alkylxanthines and to develop novel inhibitors of cyclic AMP-specific phosphodiesterase (PDE IV), a series of heterocycle-condensed purines were designed and synthesized. Some of these new compounds had similar or more potent and selective inhibitory activity against PDE IV than known PDE IV inhibitors. The tracheal-relaxant activity of these compounds was closely correlated with their PDE IV-inhibitory activity. Moreover, these purine analogues did not have any positive-chronotropic action or adenosine-antagonistic action on isolated heart preparations, which are the particular adverse reactions of alkylxanthines. Among them, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[1,2-i]purin-5-one (1c), which was the most selective and potent PDE TV inhibitor, did not cause emesis in Suncus murinus at a dosage range of 10-100 mg/kg (po), while an imidazole analogue of 1c (4c) and known PDE IV inhibitors such as rolipram and denbufylline caused emesis even at 10 or 30 mg/kg.
• US5270316A
  申请人：——

  公开号：US5270316A

  公开（公告）日：1993-12-14
• A convenient synthesis of tricyclic purine derivatives
  作者：Junichi Shimada、Takeshi Kuroda、Fumio Suzuki

  DOI：10.1002/jhet.5570300141

  日期：1993.1

  A convenient synthesis of new heterocycles such as 7,8-dihydro-1H-imidazo[2,1-i]purin-5(4H)-ones (2, n = 0) and 5,6-dihydro-1H-imidazo[2,1-b]purin-9(8H)-ones (3) was described. The syntheses of 2 and 3 were accomplished by treatment of 6-methylthio-7H-purin-2(3-H)-ones 7 or 2-benzylthio-1-methyl-9-triphenylmethyl-9H-purin-6(1H)-one (15) with appropriate aminoalcohol followed by dehydrative cyclization

  方便合成新的杂环，例如7,8-dihydro-1 H-咪唑并[2,1- i ] purin-5（4 H）-ones（2，n = 0）和5,6-dihydro-1 H描述了-咪唑并[2，1 - b ]嘌呤-9（8 H）-一（3）。通过处理6-甲硫基-7 H-嘌呤-2（3- H）-ones 7或2-苄硫基-1-甲基-9-三苯基甲基-9 H-嘌呤-6（1 ）来完成2和3的合成。H）一（15）和适当的氨基醇，然后使用亚硫酰氯进行脱水环化。通过6-羟基-2-巯基嘌呤（12）的苄基化，三苯甲基化和N-甲基化来有效地制备化合物15。